Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Key Finding of DM Treatment with Combination, a MuLticenter, Randomized, Parallel, Gathering Information of Phase 4 Trial to Evaluate the Efficacy and Safety of Dapagliflozin or Pioglitazone Add-on to Metformin and DPP-4 Inhibitor in Patients with Type 2 Diabetes

NCT06875193 is registered in ClinicalTrials.gov with Dong Wha Pharmaceutical Co. Ltd. as lead sponsor.

NCT NCT06875193
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06875193 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Key Finding of DM Treatment with Combination, a MuLticenter, Randomized, Parallel, Gathering Information of Phase 4 Trial to Evaluate the Efficacy and Safety of Dapagliflozin or Pioglitazone Add-on to Metformin and DPP-4 Inhibitor in Patients with Type 2 Diabetes
Lead sponsor
Dong Wha Pharmaceutical Co. Ltd.
Phase
Phase 4
Overall status
Recruiting
Start date
May 28, 2024
Completion date
December 31, 2025
Enrollment
196 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

type2diabetes